Matching articles for "ambrisentan"
Issue 1737 · September 15, 2025 Free
In Brief: Embryotoxicity REMS Removal for Endothelin Receptor Antagonists

The FDA has removed the Risk Evaluation and Mitigation Strategy (REMS) requirement for the endothelin receptor antagonists ambrisentan ( Letairis , and generics), bosentan ( Tracleer , and generics),…

Med Lett Drugs Ther. 2025 Sep 15; 67(1737):152 doi:10.58347/tml.2025.1737e
The FDA has removed the Risk Evaluation and Mitigation Strategy (REMS) requirement for the endothelin receptor antagonists ambrisentan ( Letairis , and generics), bosentan ( Tracleer , and generics), macitentan ( Opsumit , and generics; Opsynvi) , and aprocitentan (Tryvio) , and the endothelin receptor antagonist and angiotensin II receptor antagonist sparsentan (Filspari) that was initially implemented because of a possible risk of embryofetal toxicity.
Issue 1704 · June 10, 2024
Aprocitentan (Tryvio) for Hypertension

The FDA has approved the dual endothelin receptor antagonist aprocitentan ( Tryvio – Idorsia) for use in combination with other antihypertensive drugs to treat hypertension in adults whose blood pressure is…

Med Lett Drugs Ther. 2024 Jun 10; 66(1704):92-3 doi:10.58347/tml.2024.1704b
The FDA has approved the dual endothelin receptor antagonist aprocitentan ( Tryvio – Idorsia) for use in combination with other antihypertensive drugs to treat hypertension in adults whose blood pressure is not adequately controlled on other drugs. Three other dual endothelin receptor antagonists, ambrisentan ( Volibris , and generics), bosentan ( Tracleer , and generics), and macitentan (Opsumit) , are available in the US for treatment of pulmonary arterial hypertension.
Issue 1702 · May 13, 2024
Sotatercept (Winrevair) for Pulmonary Arterial Hypertension

The FDA has approved sotatercept-csrk ( Winrevair – Merck), a first-in-class activin signaling inhibitor, to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical…

Med Lett Drugs Ther. 2024 May 13; 66(1702):73-5 doi:10.58347/tml.2024.1702a
The FDA has approved sotatercept-csrk ( Winrevair – Merck), a first-in-class activin signaling inhibitor, to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events in adults with WHO Group 1 pulmonary arterial hypertension (PAH).
Issue 1488 · February 15, 2016
Selexipag (Uptravi) for Pulmonary Arterial Hypertension

The FDA has approved selexipag ( Uptravi – Actelion), an oral selective prostacyclin IP receptor agonist, for treatment of pulmonary arterial hypertension (PAH). Treprostinil (Orenitram) , an oral…

Med Lett Drugs Ther. 2016 Feb 15; 58(1488):21-3
The FDA has approved selexipag ( Uptravi – Actelion), an oral selective prostacyclin IP receptor agonist, for treatment of pulmonary arterial hypertension (PAH). Treprostinil (Orenitram) , an oral prostacyclin analog, was approved earlier for this indication.
Issue 1485 · January 4, 2016
Ambrisentan (Letairis) and Tadalafil (Adcirca) for Pulmonary Arterial Hypertension

The FDA has approved the use of ambrisentan (Letairis) and tadalafil (Adcirca) together for treatment of pulmonary arterial hypertension (PAH). It is the first 2-drug regimen to be approved for this indication.

Med Lett Drugs Ther. 2016 Jan 4; 58(1485):2-4
The FDA has approved the use of ambrisentan (Letairis) and tadalafil (Adcirca) together for treatment of pulmonary arterial hypertension (PAH). It is the first 2-drug regimen to be approved for this indication.
Issue 1437 · March 3, 2014
Riociguat (Adempas) for Pulmonary Hypertension

The FDA has approved the sGC stimulator riociguat (rye" oh sig' ue at; Adempas – Bayer) for oral treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)…

Med Lett Drugs Ther. 2014 Mar 3; 56(1437):17-9
The FDA has approved the sGC stimulator riociguat (rye" oh sig' ue at; Adempas – Bayer) for oral treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) following surgery or when surgery is not an option. It is the first drug to be approved for treatment of CTEPH.
Issue 1436 · February 17, 2014
Macitentan (Opsumit) for Pulmonary Arterial Hypertension

The FDA has approved macitentan (ma" si ten' tan; Opsumit – Actelion), for oral treatment of pulmonary arterial hypertension (PAH). Macitentan is the second nonselective endothelin receptor antagonist…

Med Lett Drugs Ther. 2014 Feb 17; 56(1436):15-6
The FDA has approved macitentan (ma" si ten' tan; Opsumit – Actelion), for oral treatment of pulmonary arterial hypertension (PAH). Macitentan is the second nonselective endothelin receptor antagonist approved for PAH. It is a derivative of bosentan (Tracleer) , which is also manufactured by Actelion, and is scheduled to become available generically in 2015. Riociguat (Adempas) , another new drug for this indication, will be reviewed in a future issue. Volibris
Issue 1324 · November 2, 2009
Tadalafil (Adcirca) for Pulmonary Arterial Hypertension

The FDA has approved use of tadalafil ( Adcirca - Lilly/United Therapeutics) for treatment of pulmonary arterial hypertension (PAH).

Med Lett Drugs Ther. 2009 Nov 2; 51(1324):87-8
The FDA has approved use of tadalafil ( Adcirca - Lilly/United Therapeutics) for treatment of pulmonary arterial hypertension (PAH).
Issue 1272 · October 22, 2007
Ambrisentan (Letairis) for Pulmonary Arterial Hypertension

Ambrisentan ( Letairis - Gilead), a selective endothelin type A (ET A ) receptor antagonist, has been approved by the FDA for treatment of symptomatic patients (WHO class II or III) with pulmonary arterial…

Med Lett Drugs Ther. 2007 Oct 22; 49(1272):87-8
Ambrisentan ( Letairis - Gilead), a selective endothelin type A (ET A ) receptor antagonist, has been approved by the FDA for treatment of symptomatic patients (WHO class II or III) with pulmonary arterial hypertension (PAH).